Lin28a protects against diabetic cardiomyopathy through Mst1 inhibition

Penghua You1,2, Zheng Cheng1, Xiaomin He3

  • 1Department of Cardiology, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.

Insights

Lin28a protects against diabetic cardiomyopathy by inhibiting Mst1 and promoting autophagy. This study reveals Lin28a

Area of Science:

  • Cardiovascular Biology
  • Metabolic Diseases
  • Cellular Mechanisms

Background:

  • Diabetic cardiomyopathy (DCM) involves cardiac dysfunction due to diabetes.
  • Lin28a is known to improve glucose metabolism and insulin sensitivity.
  • The specific role of Lin28a in DCM pathogenesis remains unclear.

Purpose of the Study:

  • To investigate the protective effects of Lin28a against DCM.
  • To elucidate the underlying molecular mechanisms of Lin28a in DCM.

Main Methods:

  • Primary neonatal mouse cardiomyocytes were treated with Lin28a or Mst1 shRNA under high glucose conditions.
  • Assessed cardiomyocyte apoptosis, autophagy, mitochondrial function, and cytokine levels.
  • Utilized autophagy inhibitor (3-methyladenine) and Mst1 knockdown to explore pathway dependency.

Main Results:

  • Lin28a overexpression and Mst1 knockdown mitigated high glucose-induced cardiomyocyte injury.
  • Both interventions improved mitochondrial morphology, reduced apoptosis, and enhanced autophagy.
  • Protective effects were dependent on autophagy and Mst1 inhibition, with Lin28a acting via Akt to inhibit Mst1.

Conclusions:

  • Lin28a protects cardiomyocytes from high glucose injury by inhibiting Mst1 and promoting autophagy.
  • Lin28a's protective effects in DCM are mediated through the Akt/Mst1 pathway.
  • Targeting Lin28a may offer a therapeutic strategy for diabetic cardiomyopathy.

Related Concept Videos